A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric ...

Respiratory syncytial virus, or RSV, is a single-stranded virus that originates from RNA. Illness from RSV is considered an infectious disease, usually leading to an infection of the upper ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine clesrovimab-cfor (Enflonsia) for preventing respiratory syncytial virus (RSV) in ...

Respiratory syncytial virus (RSV) causes severe illness in millions of young children each year.1 Globally, it is estimated that over 100 000 children younger than 5 years die each year from RSV; 97% ...

Background: Respiratory syncytial virus (RSV) ... Cite this: Medical and Economic Impact of a Respiratory Syncytial Virus Outbreak in a Neonatal Intensive Care Unit - Medscape - Dec 01, 2005.

Respiratory syncytial virus (RSV) is a common viral infection that may lead to serious complications in certain groups. Since 2023, vaccines are now available and are highly recommended ...

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

The U.S. Centers for Disease Control and Prevention's revamped vaccine advisory panel on Wednesday postponed its vote on the ...